Rapid weight loss from certain metabolic drugs can weaken bones as much as long-term steroid use
While GLP-1 agonists revolutionize weight management, their rapid metabolic effects can trigger bone density loss comparable to long-term steroid use, increasing the risk of osteoporosis by nearly thirty percent.
GLP-1 receptor agonists trigger rapid weight loss that can inadvertently weaken the skeletal system. While typical postmenopausal bone loss averages only 1-2% annually, patients on these metabolic drugs face accelerated resorption and a 30% higher risk of osteoporosis. This decline is driven by both decreased mechanical loading on the frame and the direct inhibition of osteoblast activity.
There's more to this story — open the app to keep reading.
Continue Reading in App
1 more paragraphs · plus a 2-question quiz